This suggests that the effects of CDK inhibitors are mediated, at least in part, by increasing deregulated E2F1 activity, supporting the proposed treatment strategy of enhancing deregulated E2F activity in cancer cells, specifically inducing apoptosis. Here, E2F1 is linked to cancer.